Talk:Superoxide dismutase mimetics

GC4419 has clinical trial results edit

Latest comment: 5 years ago1 comment1 person in discussion

New drug could prevent debilitating side effect of cancer treatment says FDA has granted GC4419 breakthrough therapy status - but not sure what chemical category it is in. - Rod57 (talk) 11:18, 7 September 2018 (UTC)Reply

MnTBAP does not work as a SOD mimetic edit

An article published in the Journal of Biological Inorganic Chemistry in 2008 shows that the pure MnTBAP does not have SOD mimetic activity. The SOD mimetic activity detected from the studies on MnTBAP were actually from impurities present on the Mn-porphyrin sample used.^[1]

References

^ Rebouças, Júlio; Spasojević, Ivan; Batinić-Haberle, Ines (February 2008). "Pure manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)porphyrin (MnTBAP) is not a superoxide dismutase mimic in aqueous systems: a case of structure–activity relationship as a watchdog mechanism in experimental therapeutics and biology" (PDF). Journal of Biological Inorganic Chemistry. 13 (2): 289–302. doi:10.1007/s00775-007-0324-9. Retrieved 1 March 2019.

Add topic

[1] Rebouças, Júlio; Spasojević, Ivan; Batinić-Haberle, Ines (February 2008). "Pure manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)porphyrin (MnTBAP) is not a superoxide dismutase mimic in aqueous systems: a case of structure–activity relationship as a watchdog mechanism in experimental therapeutics and biology" (PDF). Journal of Biological Inorganic Chemistry. 13 (2): 289–302. doi:10.1007/s00775-007-0324-9. Retrieved 1 March 2019.

[1]